Pyxis Oncology Inc (NAS:PYXS)
$ 1.13 (0%) Market Cap: 70.00 Mil Enterprise Value: -15.59 Mil PE Ratio: 0 PB Ratio: 0.68 GF Score: 33/100

Pyxis Oncology Inc To Acquire Apexigen Inc Call Transcript

May 24, 2023 / 01:00PM GMT
Release Date Price: $3.34 (-10.46%)
Operator

Good day, and thank you for standing by. Welcome to the Pyxis Oncology Corporate Update Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Lara Sullivan, CEO. Please go ahead.

Lara S. Sullivan
Pyxis Oncology, Inc. - CEO, President & Director

Thank you. Good morning, and thank you for joining us today. My name is Lara Sullivan, and I'm the CEO of Pyxis Oncology. Thank you for joining us to discuss Pyxis Oncology's acquisition of Apexigen and the tremendous value we believe it can create for patients and investors. Joining me on today's call is Dr. Xiaodong Yang, Founder and CEO of Apexigen, and Pam Connealy, CFO and COO of Pyxis Oncology.

Next slide, please. Please note that today's presentation includes forward-looking statements. We encourage you to review these statements, which are available on our website.

Moving to Slide 2. I'm pleased to tell you why we are excited about our acquisition of Apexigen. This

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot